Tag: Aldeyra Therapeutics

March 12, 2020

Aldeyra Therapeutics Reports Full-Year 2019 Financial Results

Aldeyra Therapeutics reported financial results for the year ended December 31, 2019 and provided an update on anticipated clinical milestones.
May 17, 2017

Aldeyra Therapeutics Reveals Results from ADX-102 Trial

Aldeyra Therapeutics presented the results from their Phase 2 clinical trial of ADX-102 at this years' meeting of the Association...
May 15, 2017

Aldeyra Therapeutics Shares Financials for Q1 2017

Aldeyra Therapeutics released their financial results for their first quarter of 2017 and provided a corporate update.
April 27, 2017

Aldeyra Gets First Patient Enrolled in Phase 3 Trial

Aldeyra Therapeutics enrolled the first patient in their Phase 3 clinical trial of ADX-102.
April 20, 2017

Aldeyra Gets Orphan Drug Designation for ADX-102

Aldeyra Therapeutics received an orphan drug designation by the US Food and Drug Administration for ADX-102 in treating rare disease...
April 18, 2017

Aldeyra Doses Last Patient in Allergic Conjunctivitis Trial

Aldeyra Therapeutics announced the last patient dosing for its Phase 2b clinical trial of ADX-102 in allergic conjunctivitis.
February 14, 2017

Aldeyra Therapeutics, Inc. Prices Public Offering of Common Stock

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to...